Mapatumumab, A TRAIL Receptor 1 Agonist Antibody, Induces Apoptosis in Bortezomib Resistant Multiple Myeloma.

被引：0
|
作者：
Ghoshal, Pushpankur [1 ]
Chitta, Kasyapa [1 ]
Vujcic, Slavoljub [1 ]
Gaddy, Jacquelyne [1 ]
Miles, Kiersten M. [1 ]
Stein, Leighton [1 ]
Sher, Taimur [1 ]
Lee, Kelvin P. [1 ]
Chanan-Khan, Asher A. [1 ]
机构：
[1] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1106 / 1107
页数：2
相关论文
共 50 条
  • [11] Proteasome inhibitor bortezomib augments tumor therapy with TRAIL receptor agonist antibody MD5-1
    Shanker, Anil
    Brooks, Alan D.
    Tristan, Carlos A.
    Sayers, Thomas J.
    CANCER RESEARCH, 2006, 66 (08)
  • [12] Lenalidomide treatment interferes with Ras/MAPK activation and induces apoptosis in multiple myeloma.
    Mendy, Derek
    Gaidarova, Svetlana
    Brady, Helen
    Lopez-Girona, Antonia
    CANCER RESEARCH, 2009, 69
  • [13] Distinct dynamic profiles for NPI-0052-and bortezomib-induced apoptosis in multiple myeloma.
    Chauhan, Dharminder
    Singh, Ajita
    Velankar, Mugdha
    Hideshima, Teru
    Ovaa, Huib
    Berkers, Celia
    Bianchi, Giada
    Sitia, Roberto
    Munshi, Nikhil C.
    Richardson, Paul
    Palladino, Michael A.
    Anderson, Kenneth C.
    BLOOD, 2006, 108 (11) : 970A - 970A
  • [14] Inhibition of the insulin like growth factor 1 receptor by a specific monoclonal antibody in multiple myeloma.
    Gualberto, A
    Alsina, M
    Lacy, M
    Poutney, S
    Birgin, A
    Littman, B
    Melvin, C
    Petersen, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 203S - 203S
  • [15] Inhibition of Wnt/β-Catenin Pathway with ICG-001 Induces Apoptosis in Multiple Myeloma.
    Grigson, Eileen R.
    Pisklakova, Alexandra
    Weissman, Brittany
    Nefedova, Yulia
    BLOOD, 2012, 120 (21)
  • [16] Solamargine induces autophagy-mediated apoptosis and enhances bortezomib activity in multiple myeloma
    Han, Qiaoyan
    Bai, Hua
    Xu, Yong
    Zhou, Min
    Zhou, He
    Dong, Xiaoqing
    Chen, Bing
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2022, 49 (06) : 674 - 685
  • [17] A phase 1 trial of lenalidomide (REVLIMID®) with bortezomib (VELCADE®) in relapsed and refractory multiple myeloma.
    Richardson, P
    Schlossman, R
    Munshi, N
    Avigan, D
    Jagannath, S
    Alsina, M
    Doss, D
    McKenney, M
    Hande, K
    Farrell, M
    Gorelik, S
    Colson, K
    Warren, D
    Lunde, L
    Michelle, R
    Cole, G
    Mitsiades, C
    Hideshima, T
    Myers, T
    Knight, R
    Anderson, K
    BLOOD, 2005, 106 (11) : 110A - 111A
  • [18] Changes in Mcl-1 and Bim expression with bortezomib and melphalan therapy for multiple myeloma.
    Popat, R
    Goff, L
    Oaekervee, HE
    Cavenagh, JD
    Joel, SP
    BLOOD, 2005, 106 (11) : 697A - 697A
  • [19] hvTRA, a novel TRAIL receptor agonist, induces apoptosis and sustained growth retardation in melanoma
    Fleten, Karianne G.
    Florenes, Vivi Ann
    Prasmickaite, Lina
    Hill, Oliver
    Sykora, Jaromir
    Maelandsmo, Gunhild M.
    Engesaeter, Birgit
    CELL DEATH DISCOVERY, 2016, 2
  • [20] hvTRA, a novel TRAIL receptor agonist, induces apoptosis and sustained growth retardation in melanoma
    Karianne G Fleten
    Vivi Ann Flørenes
    Lina Prasmickaite
    Oliver Hill
    Jaromir Sykora
    Gunhild M Mælandsmo
    Birgit Engesæter
    Cell Death Discovery, 2
12345